Mithrl raises $20M Series A for AI drug-discovery platform

An AI layer for scientific decisions

Mithrl’s platform lets research teams deploy auditable AI agents inside drug-development workflows to examine experiments, test hypotheses and synthesize evidence. The next-generation Mithrl-1 system adds agent orchestration for model routing, token efficiency and context management, helping scientists connect generated insights to the underlying biomedical evidence.

Use of funds

Roll out the second-generation Mithrl-1 platform

Funding history

Sep 16, 2026Series A · This round$20M

Sources

Similar rounds

All AI rounds →

TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A · Oct 9, 2026

Arena

Provides crowdsourced AI model performance leaderboards

$200MSeries B · Oct 8, 2026

Preference Model

Reinforcement-learning environments that help AI labs train models to solve tasks without exploiting flaws in the grading system.

$16MSeed · Oct 7, 2026

Nous Research

Open-source AI models and the Hermes agent, which retains project memory and reusable skills across tasks.

$90MSeries B · Oct 7, 2026